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Abstract
Oxidative balance is emerging as an important issue in understanding the pathogenesis of Alzheimer’s disease.
Examination of Alzheimer’s disease brain has demonstrated a great deal of oxidative damage, associated with both hallmark
pathologies (senile plaques and neurofibrillary tangles) as well as in normal appearing pyramidal neurons. While this suggests
that oxidative stress is a proximal event in Alzheimer’s disease pathogenesis, the mechanisms by which redox balance is
altered in the disease remains elusive. Determining which of the proposed sources of free radicals, which include
mitochondrial dysfunction, amyloid-L-mediated processes, transition metal accumulation and genetic factors like
apolipoprotein E and presenilins, is responsible for redox imbalance will lead to a better understanding of Alzheimer’s
disease pathogenesis and novel therapeutic approaches. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
For Alzheimer’s disease (AD), the majority of re-
search resources have been dedicated to studies on
the pathogenesis of the intraneuronal ¢lamentous in-
clusions, known as neuro¢brillary tangles (NFT),
and the extracellular senile plaques. This focus has
often been detrimental to the advancement of other
theories. Consequently, there is a large void in our
understanding of the pathogenesis of AD, namely
the underlying mechanism of the disease. Nonethe-
less, in recent years, research has clearly pointed to
the importance of oxidative imbalance in AD. Here,
we review some of these fundamental insights that
have indicated the importance of oxidative stress
and free radical damage to the pathogenesis of AD.
2. Oxidative damage
Under normal conditions, damage by oxygen rad-
icals is kept in check by an e⁄cient array of antioxi-
dant systems that display extensive redundancy (e.g.
the simultaneous metabolism of H2O2 by catalase
and glutathione peroxidase). However, during patho-
logical conditions, the oxidant versus antioxidant
balance is necessarily altered, either primarily or sec-
ondarily. Oxidative damage occurs when the oxida-
tive balance is disturbed such that reactive oxygen
production exceeds cellular anti-oxidant defenses.
The oxidative damage found in AD includes ad-
vanced glycation end products [1^4], nitration [5,6],
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lipid peroxidation adduction products [7,8], carbon-
yl-modi¢ed neuro¢lament protein and free carbonyls
[9^11] (Fig. 1). While not necessarily pathogenic, as
discussed below, it is important to realize that this
damage selectively involves all neurons in popula-
tions vulnerable to death in AD.
2.1. Oxidative damage, neuro¢brillary tangles and
senile plaques
Examination of the spatio-temporal relationship
between the presence of oxidative modi¢cation and
the hallmark lesions of AD reveal a paradox. We
found that stable glycation products are predomi-
nantly associated with NFT and AL deposits [1],
whereas reversible or rapidly degraded adduction
products are predominately in the cytoplasm of vul-
nerable neurons. In fact, damage to short-lived mol-
ecules appears to be restricted to cytosolic compart-
ments.
In order to address where reactive oxygen is pro-
duced, we focused our e¡orts on ¢nding a marker
that results from primary attack and which involves
damage to a cell constituent with a short half-life.
This allows for the examination of events that pro-
ceed those detected by more complex secondary re-
actions. Proteins fail in the latter aspect of the two
criteria mentioned because modi¢cations associated
with crosslinking slow their turnover. Therefore,
crosslink modi¢cations of proteins, while useful to
assess history, may reveal less of the current state.
Detection of 8-hydroxyguanosine (8OHG), a nucleic
acid modi¢cation predominantly derived from hy-
droxide (OH) attack of guanidine, allows for assess-
ment of more immediate oxidative damage. 8OHG
has been found to be greatly increased in the cyto-
plasmic RNA of vulnerable neuronal populations
[12]. Likewise, neurons containing NFT have ex-
tremely low levels of 8OHG (i.e. current oxidative
stress status) despite an obvious history of oxidative
damage (i.e. advanced glycation endproducts or lipid
peroxidation). Notably, however, cases of AD with
the most extensive amyloid-L (AL) deposits show the
lowest levels of 8OHG. These ¢ndings seem mark-
edly contradictory considering reports that AL is a
major source of oxidative free radicals and/or a toxic
agent in AD [13] and instead suggests that both AL
and NFT may be cellular compensations for in-
creased oxidative stress and serve antioxidant func-
tions.
The hypothesis that AL plays an antioxidant func-
tion is supported by a study of Down’s syndrome
patients, a disease where AL deposits begin in the
late teens and in which oxidative stress has been
implicated [14]. As with AD, in Down’s cases, AL
deposition follows, rather than precedes, increased
8OHG and 8OHG levels decline to control levels
(r = 0.98) after AL plaques form. Therefore, given
Fig. 1. Schematic showing oxidative-mediated protein modi¢cations are generated via free radicals and oxidative intermediates. Pro-
teins can be modi¢ed and crosslinked by glycation, autoxidation and reactive aldehydes. These processes are largely synergistic such
that the protein modi¢cations involve production of redox-active species that potentiate free radical autoxidation. (Reproduced with
permission from Smith et al., Trends Neuroscience 18(4) (1995) 172^176.)
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that oxidative damage occurs prior to the appearance
of other abnormalities, it is unlikely that AL, ad-
vanced glycation endproducts or in¢ltration of mi-
croglia are primary contributors. However, redox-
active iron, especially in conjunction with mitochon-
drial abnormalities, represent an early and, equally
importantly, cytoplasmic base for the generation of
oxidizing species.
3. Sources of oxidative stress in Alzheimer’s disease
In AD, there are a number of contributory sources
that are thought to play an important role in free
radical production. (1) Iron, in a redox-active state,
is increased in NFT as well as in AL deposits [15,16]
(Fig. 2). Iron catalyzes the formation of OH from
H2O2 as well as the formation of advanced glycation
end products. Furthermore, aluminum, which also
accumulates in NFT-containing neurons [15], stimu-
lates iron-induced lipid peroxidation [17]. (2) Acti-
vated microglia, such as those that surround most
senile plaques [18], are a source of NO and O32
[19] that can react to form peroxynitrite, leaving ni-
trotyrosine as an identi¢able marker [5,6]. (3) AL,
itself, has been directly implicated in reactive oxygen
formation through peptidyl radicals [13,20,21]. (4)
Advanced glycation end products in the presence of
transition metals can undergo redox cycling with
consequent production of reactive oxygen [4,22,23].
Additionally, advanced glycation end products, as
well as AL, activate speci¢c receptors, such as the
receptor for advanced glycation end products
(RAGE) and the class A scavenger-receptor, to in-
crease reactive oxygen production [24,25]. (5) Abnor-
malities in the mitochondrial genome [26,27] or de¢-
ciencies in key metabolic enzymes [28^32] suggest
that metabolic abnormalities a¡ecting mitochondria
may be the major, and possibly initiating, source of
reactive oxygen in AD.
Quantitative analysis of the co-localization of
mtDNA deletions and 8OHG in AD cases demon-
strates a strong positive correlation (r = 0.934). How-
ever, mitochondrial DNA, even that which contains
the 5 kb deletion, is relatively spared from oxidative
damage (i.e. the formation of 8OHG) in comparison
to cytoplasmic nucleic acid. We therefore suspect
that mitochondrial abnormalities correlate with, but
do not directly cause, reactive oxygen. This may be
due to the fact that hydroxide radicals, which are
responsible for the formation of 8OHG, tend to be
fairly short-lived in solution and have a sphere of
di¡usion of only 2 nm. Therefore, since damage is
topographically distinct, it is likely that OH radical
formation occurs in the cytoplasm rather than the
mitochondria and that mtDNA is relatively spared
due to their inability to di¡use through the mito-
chondrial membrane. However, abnormal mitochon-
dria may produce excess H2O2 through conversion of
O32 by mitochondrial superoxide dismutase. Such
H2O2 is readily di¡usible and relatively stable, that
is, until confronting redox-active transition metals
where Fenton chemistry drives the production of
OH.
Fig. 2. Redox-active iron in AD brain (A) is strongly associated with the hallmark pathologies, namely neuro¢brillary tangles (arrow-
heads) and senile plaques (arrows). By marked contrast, there is little iron deposition in age-matched control brain (B). Scale bar: 200
Wm. (Reproduced with permission from Smith et al. [16].)
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Recent histochemical studies have demonstrated
that the direct detection of redox activity in lesions
of AD is inhibited by prior exposure of tissue sec-
tions to copper and iron selective chelators [33]. The
activity can be reinstated following re-exposure of
the chelator-treated sections to either copper or
iron salts suggesting that redox imbalance in AD is
dependent on these metals. It is probable that accu-
mulation of iron and copper is a major source of the
production of reactive oxygen, which are in turn re-
sponsible not only for the numerous oxidative stress
markers that appear on NFT and senile plaques, but
also for the more global oxidative stress parameters
observed in AD.
4. Genetics and oxidative stress
A number of mechanisms have been suggested for
AL-associated neurotoxicity [21,34,35], including
membrane depolarization [36], increased sensitivity
to excitotoxins [37], and alterations in calcium ho-
meostasis [38]. However, the in£uences of AL and
other genetic factors on the pathogenesis of AD
may be mediated through their e¡ects on oxidative
homeostasis. As discussed, in vivo AL appears to
play a protective role. However, like all antioxidants,
under certain conditions, AL also has pro-oxidant
abilities. Indeed, in vitro neuronal damage by AL
seems to be a direct result of free radicals, such
that the e¡ect can be attenuated by application of
antioxidants like vitamin E [39,40] and catalase
[41,42].
Mutations in the human presenilin genes 1 and 2
[43,44] are genetic factors linked to early onset of
AD. Although their pathogenic mechanism are not
fully understood at this point, a role for oxidative
stress has been suggested. Increased presenilin 2 ex-
pression increases DNA fragmentation and produces
apoptotic changes [45], which are both important
consequences of oxidative damage. Apolipoprotein
E is a protein that has been found to confer in-
creased susceptibility when the ApoE4 allele is
present. ApoE has been shown to be adducted with
the highly reactive lipid peroxidation product, hy-
droxynonenal, in AD brains and cerebrospinal £uid
[46]. Furthermore, ApoE is a strong chelator of cop-
per and iron, both of which are important redox-
active transition metals [47]. Another suggested ge-
netic risk factor, bleomycin hydrolase genotype, is
also associated with alterations in redox homeostasis
[48].
5. Conclusion
The fact that oxidative stress plays an important
role in AD pathogenesis seems clear given the evi-
dence that research has recently provided. Markers
of oxidative damage include the increase of HO-1
and 8OHG in AD brain as compared with controls.
In addition, the hallmark structures of AD, NFT
and senile plaques, are altered in ways characteristic
of oxidative damage including AGE-modi¢cation,
protein crosslinking and carbonyl- and acyl-modi¢-
cation. Although the source of the shift in oxidative
homeostasis is still unclear, current evidence points
to the fact that changes in the balance of redox tran-
sition metals, especially iron and copper, are key in
the process. Both Fe and Cu are present at signi¢-
cantly elevated levels in AD neuropil, and detection
of redox activity in AD brain can be attenuated by
chelators of these key metals. It has also been dem-
onstrated that many of the proteins that are impor-
tant in their regulation, including ferritin and ceru-
loplasmin, show altered expression in AD and other
neurodegenerative disorders. These changes could, in
part, be responsible for the oxidative imbalance or
may represent an attempted antioxidant response by
a¡ected cells. Taken as a whole, this research assigns
a signi¢cant role to oxidative stress in AD.
However, the key aspect of the degree of cognitive
decline in neurodegenerative disease is selective neu-
ronal death. Our ¢ndings that neurons displaying
protein damage also show an oxidative stress re-
sponse is still in need of a mechanism that links
damage and death. Determining the relative contri-
bution of sugar- or lipid-adduction reactions, as well
as direct side-chain oxidation, to the properties of
abnormal inclusions will provide insight into the
mechanism linking damage and death. This in turn
may allow for the development of rational therapeu-
tic protocols for speci¢c neurodegenerative diseases,
e.g. using water- versus lipid-soluble antioxidants [49]
or free-radical versus carbonyl scavengers. We are
encouraged by the preliminary epidemiological and
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clinical studies suggesting that inhibitors of oxidative
stress and glycation are e¡ective in reducing the clin-
ical manifestation of neurodegenerative diseases
[50,51].
In recent years, there has been an increased aware-
ness of the seminal role that both oxidative stress
and redox-active transition metals play in AD as
well as other neurodegenerative diseases. The stage
is now set to critically examine the importance of
these basic research ¢ndings as they are translated
into therapeutic modalities, such as the clinical use
of antioxidants and chelating agents. The next 2^3
years will be truly fascinating to watch unravel.
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